Physician profile
Bruce Suckling
NPI 1891749495
$2,963.68
in general payments reported to CMS, 2019-2025
32 companies · $284 in 2025
The $284 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $598 · 2020: $649 · 2021: $395 · 2022: $490 · 2023: $266 · 2024: $281 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $832.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $831.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,152.02 | 2019-2025 | Tezspire, Imfinzi, Fasenra |
| Grifols USA, LLC | $305.93 | 2019-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.33 | 2019-2022 | |
| Intuitive Surgical, INC. | $130.53 | 2024 | |
| Glaxosmithkline, LLC. | $128.10 | 2019-2024 | Nucala |
| United Therapeutics Corporation | $122.93 | 2020-2022 | |
| Philips North America LLC | $119.10 | 2019-2025 | Vest Therapy Und |
| Pulmonx Corporation | $79.72 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $73.27 | 2021-2025 | Dupixent |
| Genentech USA, INC. | $67.77 | 2019-2022 | |
| Actelion Pharmaceuticals US, INC. | $62.46 | 2019-2024 | Opsumit |
| Gilead Sciences, INC. | $53.32 | 2021-2022 | |
| Mylan Specialty L.P. | $49.44 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $45.34 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $36.88 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $36.00 | 2019 | |
| Merck Sharp & Dohme LLC | $33.86 | 2019-2023 | |
| Viatris Specialty LLC | $27.16 | 2025 | Yupelri |
| Liquidia Technologies, INC. | $25.42 | 2025 | Yutrepia |
| Movair INC | $24.82 | 2025 | Luisa |
| Jazz Pharmaceuticals INC. | $24.15 | 2021 | |
| Alexion Pharmaceuticals, INC. | $24.08 | 2022 | |
| Inogen, INC. | $22.55 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.03 | 2024 | Glassia |
| Bayer Healthcare Pharmaceuticals INC. | $19.99 | 2021 | |
| Mallinckrodt Hospital Products INC. | $18.45 | 2021 | |
| Allergan, INC. | $18.38 | 2019 | |
| Ge Healthcare | $18.12 | 2020 | |
| Veran Medical Technologies, INC. | $17.76 | 2019 | |
| Insmed, INC. | $15.44 | 2019 | |
| Genzyme Corporation | $13.71 | 2021 | |
| La Jolla Pharmaceutical Company | $13.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Suckling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.